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In eukaryotic cells, nascent membrane or secretory
proteins are translocated into the endoplasmic reticulum
through the Sec61p translocation channel; recent
evidence suggests that, if they fail to achieve a native
conformation, they are translocated back into the cytosol
by the same route and degraded by the proteasome.
Address: Section of Immunobiology, Howard Hughes Medical Institute,
Yale University School of Medicine, 310 Cedar Street, New Haven,
Connecticut 06510, USA.
Current Biology 1997, 7:R552–R555
http://biomednet.com/elecref/09609822007R0552
© Current Biology Ltd ISSN 0960-9822
It has long been recognized that misfolded forms of
proteins normally destined for secretion or surface expres-
sion by eukaryotic cells fail to escape from the endoplas-
mic reticulum (ER). Misfolding may occur because of a
mutation or because the protein is a subunit of a hetero-
multimeric species and the other subunits are absent. An
example of the latter situation occurs in plasma cells,
where variants that synthesize immunoglobulin heavy
chains, but not light chains, fail to express the heavy
chains at the cell surface or to secrete them [1]. Similarly,
T-cell receptor α and β subunits are not expressed at the
cell surface in the absence of the CD3 components that
they normally associate with [2], and major histocompati-
bility complex (MHC) class I heavy chains are not
expressed at the cell surface in the absence of their small
subunit partner, β2-microglobulin [3]. The fate of these
misfolded subunits is proteolysis, and for many years
researchers have tried to discover the mechanism of ER-
associated protein degradation. Recent work has made a
strong case that much, if not all, ER-associated proteolysis
occurs in the cytosol and is mediated by the major cyto-
solic protease, the proteasome.
Evidence that cytosolic components are required for ER-
associated proteolysis initially came from studies in yeast.
In an attempt to replicate the process in vitro, McCracken
and Brodsky [4] used isolated microsomes containing a
post-translationally translocated, non-glycosylated mutant
form of pre-pro-α factor, and found that the addition of
yeast cytosol and ATP were required to promote the
mutant protein’s degradation. The implication is that either
a cytosolic component is required to mediate or activate
proteolysis in the ER lumen, or the misfolded protein sub-
strate has to be made accessible to a protease in the cytosol.
Subsequent genetic analysis suggested that the latter inter-
pretation is correct. Werner et al. [5] found that cytosol
extracted from yeast with mutations in the pre1 and pre2
genes, which encode proteasome subunits, can promote
protein export from microsomes, but that degradation of the
exported protein is substantially reduced. Hiller et al. [6],
studying the degradation of a mutant form of the soluble
vacuolar protein carboxypeptidase yscY, found that, after
synthesis, insertion into the ER lumen and glycosylation,
the protein was translocated back to the cytoplasm, where
the glycosylated form of the enzyme was conjugated with
ubiquitin and degraded by the proteasome.
The evidence that similar mechanisms are at work in ER-
associated proteolysis in mammalian cells came from a sur-
prising source — studies of the escape mechanisms used
by human cytomegalovirus (CMV) to avoid recognition by
cytotoxic T cells. Effective recognition of virally-infected
cells depends upon the assembly and expression at the
cell surface of MHC class I molecules associated with a
peptide derived from a viral protein (for reviews, see
[7,8]). Assembly occurs in the ER, and involves the MHC-
encoded class I transmembrane glycoprotein, the β2-
microglobulin subunit, and a peptide that is generated by
cytosolic proteolysis and translocated into the ER by the
‘transporter associated with antigen processing’ (TAP).
Successful assembly satisfies the requirements of ER
quality control [9], and the MHC class I–peptide complex
is transported from the ER, via the Golgi apparatus, to the
cell surface, where cytotoxic T cells can recognize it and
kill the virally infected cell.
A number of viruses have evolved ways of disrupting the
MHC class I assembly and transport process, and CMV
has the most sophisticated set of mechanisms so far dis-
covered. Human CMV encodes a protein, US3, that causes
MHC class I molecules to accumulate in the ER and pre-
vents their transport to the cell surface [10,11]. A second
CMV protein, US6, interferes with the ability of TAP to
translocate peptides from the cytosol to the ER, thus pre-
venting assembly of MHC class I–peptide complexes
[12–14]. Two other CMV proteins, US2 and US11, were
found by Wiertz, Ploegh and co-workers [15,16] to cause
rapid retrotranslocation of MHC class I heavy chains from
the ER to the cytosol. 
In the presence of proteasome inhibitors, such as lactacystin
[17], class I heavy chains were found to accumulate in the
cytosol of CMV-infected cells. In contrast to the results in
yeast [6], the cytosolic class I molecules were in an
unglycosylated form. An N-glycanase activity has been
described in mammalian cytosol [18], and evidence was
obtained suggesting that, in the cytosolic class I heavy
chains, the asparagine residue that serves as anchor for the
glycan moiety was converted to an aspartic acid, consistent
with deglycosylation by such an enzyme. This led to the
hypothesis that MHC class I heavy chains enter the ER
lumen, acquire their N-linked glycan and, in some manner
mediated by US2 or US11, are shunted back into the
cytosol where they are deglycosylated and rapidly degraded
by the proteasome. Only in the presence of proteasome
inhibitors are the deglycosylated chains detectable.
In cells making US2 or US11, the rate of retrotransloca-
tion of MHC class I heavy chains is extremely rapid —
deglycosylated heavy chains are detectable in the cytosol
within minutes of their synthesis [15,16]. The degradation
of MHC class I molecules that occurs in the absence of
β2-microglobulin, or of peptides supplied by TAP, is
much slower, raising the question of whether this degra-
dation occurs in a similar manner to that induced by the
CMV genes. Subsequent experiments showed that
indeed it does. Mutant human cell lines lacking either
TAP or β2-microglobulin expression were found also to
accumulate deglycosylated MHC class I heavy chains in
the cytosol in the presence of proteasome inhibitors [19].
The rate of cytosolic accumulation in these cases was
again much slower than in US2 or US11 expressing cells.
A small, but variable, fraction of class I heavy chains in
normal cell lines behaved similarly [19], suggesting that
peptides might be limiting for class I assembly. Further-
more, when proper folding of class I molecules was
impeded by altering the redox potential of the ER with
the reducing agent dithiothreitol, they were similarly
translocated into the cytosol [15]. Interaction of the
translocated proteins with cytosolic chaperones, such as
heat shock protein 70 (Hsp70), may be required to main-
tain their solubility in the aqueous cytosolic environment.
From the above experiments, it is now reasonably well
established that the retrograde translocation of misfolded
proteins from the ER to the cytosol, and their subsequent
proteolysis by the proteasome, accounts for much of what is
considered ER-associated protein degradation (Figure 1).
This leads, of course, to additional important questions, the
first of which is: what is the route by which misfolded pro-
teins are expelled from the ER? The major route of access
for proteins into the ER lumen from the cytosol is the Sec
61 complex, the translocation channel responsible for the
signal-sequence-dependent entry into the ER of proteins
synthesized by membrane-associated ribosomes (reviewed
in [20]). The extreme rapidity of US2/US11-induced retro-
translocation of MHC class I heavy chains into the cytosol
led Wiertz et al. [15] to suggest that the reverse route might
also involve the translocation channel.
Integral membrane proteins with amino-terminal signal
sequences are introduced into the translocation channel
during translation by membrane-associated ribosomes.
The signal sequence is cleaved in the ER and N-linked
glycans are co-translationally added to appropriate
asparagine residues. When translation stops, the ribosome
dissociates and the protein is thought to move laterally out
of the channel by an unknown gating mechanism, allow-
ing the hydrophobic transmembrane domain to integrate
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Figure 1
The retrotranslocation of a misfolded
membrane glycoprotein from the ER to the
cytosol and its degradation by the
proteasome. After signal sequence cleavage,
the completed glycoprotein moves out of the
translocation channel into the ER membrane.
Interaction with ER chaperones normally
facilitates folding. In this case, proper folding
fails, and the molecule reinserts into the
translocation channel and is translocated
back into the cytosol, where it is
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into the ER membrane. Wiertz et al. [15,16] suggested
that the US2 and US11 proteins bind to the newly translo-
cated chains prior to their movement out of the channel,
and induce them to slide out into the cytosol. 
There is nothing about this suggestion that contradicts
current ideas about how the directionality of translocation
into the ER is maintained. The directionality of transloca-
tion may normally be maintained simply by a combination
of ongoing translation and the sequential binding and
release of ER chaperones, such as BiP. The binding and
release of chaperones are thought to prevent the acciden-
tal sliding of proteins back into the cytosol, so that the
nascent protein is translocated inexorably in one direction
by a kind of Brownian ratchet effect [21]. Theoretically,
the US2 and US11 proteins could cause retrotranslocation
by preventing chaperone binding, while being insuffi-
ciently bulky to prevent a US2–class I or US11–class I
complex from falling into the cytosol. Alternatively, a
more active process could be involved.
Wiertz et al. [15] obtained evidence that the translocation
channel is indeed the mediator of retrotranslocation in the
CMV system. Both US2 protein and class I heavy chains
were found to be physically associated with the transloca-
tion channel when proteasome inhibitors were added. In
each case, only deglycosylated forms were bound, arguing
that both US2 and class I molecules were accessible to the
N-glycanase enzyme prior to their release into the cytosol.
Deglycosylated US2 protein and class I heavy chains were
also found associated with the proteasome. This led to the
suggestion that US2 binds to newly synthesized MHC
class I molecules, perhaps co-translationally, and that the
two remain associated during retrotranslocation, deglyco-
sylation and targeting to the proteasome for degradation.
Does retrotranslocation of misfolded proteins from the ER
to the cytosol normally involve the translocation channel?
The rate of degradation of misfolded class I heavy chains
is relatively slow in the absence of US2 and US11. In
TAP-negative cells, MHC class I molecules form dimers
with β2-microglobulin prior to degradation [19], and US2
can bind to some β2-microglobulin-associated class I heavy
chains, which presumably are later degraded [15]. These
partially assembled class I molecules have almost certainly
left the translocation channel and integrated into the ER
membrane prior to their degradation. Thus, if the channel
is the normal route for retrotranslocation, a mechanism
must exist for reinserting completed molecules back into
the channel. Powerful genetic evidence that the transloca-
tion channel is involved in normal ER-associated degrada-
tion has now been obtained [22].
The new work, by Romisch and co-workers [22], uses
temperature-sensitive yeast sec61 mutants. The translo-
cation channel is a complex multimer, consisting of the
polytopic membrane protein Sec61p and two additional
subunits [20,23]. Mutants defective in Sec61p cannot
import proteins into the ER. Using microsomes from sec61
temperature-sensitive strains, mutant proteins could be
imported into the ER lumen at the permissive tempera-
ture, and their export and degradation analyzed using the
cell-free assay developed by McCracken and Brodsky [4]. 
The export of mutant pre-pro-α factor from the ER to the
cytosol was inhibited in the sec61 mutants even at a tem-
perature permissive for import. It was also shown that
mutant, but not wild-type, pre-pro-α factor could be
chemically cross-linked to Sec61p and that this binding
was enhanced in the sec61 mutants. This suggests that
misfolded secretory proteins associate with the transloca-
tion channel prior to retrotranslocation, whereas normal
proteins permanently lose the interaction once transloca-
tion and folding are completed.
What mechanisms govern the re-entry of misfolded pro-
teins into the translocation channel? It seems likely that the
system of ER chaperones responsible for ER quality control
[9] will prove to be intimately involved. Suggestively, the
initial work of McCracken and Brodsky [4] showed that
microsomes from yeast lacking the ER chaperone calnexin
were impaired in their ability to degrade mutant pre-pro-α
factor in the presence of cytosol and ATP. Additional com-
ponents that can modify the Sec61p translocation channel
so that it becomes a retrotranslocation channel are likely to
be discovered in the future.
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